Arcutis Biotherapeutics, Inc. (ARQT) Stock
2 members of Congress disclosed 6 trades in ARQT since 2022: 4 purchases and 2 sales, most recently Gilbert Cisneros (purchase, May 29, 2026). 6 of the hedge funds AlphaScala tracks reported ARQT in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $103.56M. Company insiders reported 0 open-market buys and 13 sales on SEC Form 4 in the 90 days to Nov 10, 2026.
Which members of Congress traded Arcutis Biotherapeutics, Inc. (ARQT)?
Most recent: Gilbert Cisneros (purchase, May 29, 2026); records start Jun 15, 2022.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-05-29 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-03-03 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-12-11 | partial sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2023-09-15 | sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2023-04-17 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2022-06-15 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 9, 2026.
See all ARQT political trades →Which hedge funds own ARQT?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 3.95M | $103.56M | +58% |
| Citadel Ken Griffin | 1.16M | $30.42M | +7333% |
| Millennium Management Israel Englander | 564K | $14.79M | +1043% |
| Marshall Wace | 447K | $11.72M | -82% |
| Point72 Steve Cohen | 362K | $9.50M | -39% |
| Renaissance Technologies Jim Simons (founder) | 58K | $1.53M | -87% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Arcutis Biotherapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 4, 26 | Matsuda Masaru | EVP, Chief Legal Officer | SELL | 40.0K | $1.4M |
| Nov 2, 26 | Watanabe Todd | See Remarks | SELL | 4.4K | $139K |
| Nov 2, 26 | Burnett Patrick | EVP, Chief Medical Officer | SELL | 943 | $30K |
| Nov 2, 26 | Matsuda Masaru | EVP, Chief Legal Officer | SELL | 1.2K | $39K |
| Oct 15, 26 | Welgus Howard G. | Director | SELL | 4.7K | $127K |
| Sep 16, 26 | Matsuda Masaru | See Remarks | SELL | 3.7K | $92K |
| Sep 15, 26 | Welgus Howard G. | Director | SELL | 4.7K | $114K |
| Sep 8, 26 | Matsuda Masaru | See Remarks | SELL | 10.0K | $250K |
| Aug 27, 26 | Curran Terrie | Director | SELL | 11.1K | $279K |
| Aug 27, 26 | Curran Terrie | Director | SELL | 27.1K | $677K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →ARQT price chart
Powered by TradingViewWhat does Arcutis Biotherapeutics, Inc. do?
Arcutis Biotherapeutics Inc. is a commercial-stage biopharmaceutical company specializing in medical dermatology treatments for immune-mediated skin diseases. It develops and commercializes innovative topical therapies, with its flagship product ZORYVE (roflumilast) available as a steroid-free cream and foam formulation. ZORYVE targets conditions such as plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, including approvals for various age groups like pediatrics. The company advances a broader immuno-dermatology pipeline, including Phase 2 trials for ZORYVE foam in vitiligo and hidradenitis suppurativa, and early development of ARQ-234, a CD200 receptor checkpoint agonist for atopic dermatitis. Arcutis Biotherapeutics Inc. focuses on regulatory expansions, clinical advancements, and commercial growth in the dermatology sector, addressing unmet needs in chronic inflammatory skin conditions through once-daily, leave-in applications that improve symptoms like itch and disease control.